The Vivelle-Dot (estradiol transdermal system) in a dosage strength of 0.025 mg/day has been newly approved as a treatment for postmenopausal osteoporosis. The Dot's original dosage strengths also received the new indication. It is applied to the abdomen two times a week and can been worn during normal activities and exercise.
Vivelle-Dot is made by Novogyne Pharmaceuticals, a join venture between Novartis and Noven Pharmaceuticals. The 0.025 mg/day version, the lowest dosage, is expected to be available this August.
In addition, Procter & Gamble and Aventis also have introduced a new osteoporosis offering: a once-a-week version of Actonel (risedronate sodium tablets) 35 mg for the prevention and treatment of postmenopausal osteoporosis. It was expected to be available by the middle of this month.
COPYRIGHT 2002 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2002 Gale Group
Contact
Home
A
Hydrocodone